Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients
Reuters
Oct 30
<a href="https://laohu8.com/S/TECX">Tectonic Therapeutic</a> Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients
Tectonic Therapeutic Inc. announced positive topline results from its Phase 1b Part B clinical trial evaluating TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF). The trial demonstrated that a single intravenous dose of TX45 was well tolerated and showed meaningful improvements in left heart function and pulmonary hemodynamics. No serious or severe adverse events, clinically significant changes in blood pressure, or immune-related reactions were reported. The company is also conducting the APEX Phase 2 trial of TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), with topline results expected in 2026. The Phase 1b results were presented by the company on October 29, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564789-en) on October 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.